Publications Update # 79 Last updated on Aug 4, 2025 Source: ReACT Group (https://www.reactgroup.org/) Previous PAOLA-1 (2023 Update): Final Overall Survival Results — Olaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer Next GYOEDU Resident: Ovarian Cancer Surveillance and Recurrences
